Abstract
Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
Original language | English |
---|---|
Pages (from-to) | 667-671 |
Number of pages | 5 |
Journal | Clinical Infectious Diseases |
Volume | 71 |
Issue number | 3 |
DOIs | |
Publication status | Published - 01-08-2020 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases